Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Merck Seals Deal to Acquire Bio-Techne for $11.3 Billion

Guavy AI Editorial Team
Instruments
MRK
Share

Bio-Techne Corporation (NASDAQ: TECH) reported its financial results for the fourth quarter ending June 30, 2026. The company's protein sciences segment saw a 2% increase in net sales to $231.2 million, while the diagnostics and spatial biology segment remained flat at $90.1 million.

The acquisition of Bio-Techne by Merck KGaA, Darmstadt, Germany is moving forward with an agreement announced on June 25, 2026 for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion.

More on Stocks

Stocks just now

Cisco Crushes Q4 Earnings with Record AI Orders

Stocks just now

Cisco Blows Past Guidance with Record Q4 Revenue of $17.3 Billion

Stocks just now

Cisco Blows Past Guidance with Record-Breaking Q4 Results

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy